leadf
logo-loader
RNS
viewRedx Pharma PLC

Redx Pharma plc - Admission of Placing

RNS Number : 4423J
Redx Pharma plc
22 December 2020
 

THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

THE INFORMATION COMMUNICATED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

Redx Pharma plc

("Redx" or "the Company")

 

Admission of Placing, Open Offer and Conversion Shares

&

Directors dealings

 

Alderley Park, 22 December 2020 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis announces that the Admission to trading on AIM ("admission") of the 78,639,800 Placing Shares, Open Offer Shares and Conversion Shares referred to in the Result of General Meeting announcement on 21 December 2020 became effective at 8.00 a.m. this morning.

 

Following admission of the 78,639,800 new ordinary shares, the Company confirms that it has 273,887,213 ordinary shares of 1p each with voting rights in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in Redx will be 273,887,213, which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

In addition, the Company confirms that all conditions have been met in relation to the options being granted to Lisa Anson and Richard Armer as announced on 2 December 2020.

 

Capitalised terms used in this announcement shall, unless defined otherwise, have the same meaning as in the announcement of the Placing and Open Offer made by the Company on 2 December 2020.

 

 

For further information, please contact:




Redx Pharma Plc 

T: +44 1625 469 918

Iain Ross, Chairman

Lisa Anson, Chief Executive




SPARK Advisory Partners (Nominated Adviser)

 T: +44 203 368 3550

Matt Davis/Adam Dawes




WG Partners LLP (Broker)

T: +44 20 3705 9330

Claes Spång/Chris Lee/David Wilson






FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin


 

 


 

About Redx Pharma Plc

 

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

 

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

Sarah Gordon Wild

2.

Reason for the notification

a)

Position/status

Non-executive director

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Participation in Placing and Open Offer

d)

Price(s) and volume(s)

Price: 56p pence per share

Volume: 892,858 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

22 December 2020

f)

Place of the transactions

Off-market

 

 

 

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

Lisa Anson

2.

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Participation in Placing and Open Offer

d)

Price(s) and volume(s)

Price: 56p pence per share

Volume: 89,286 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

22 December 2020

f)

Place of the transactions

Off-market

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

Iain Ross

2.

Reason for the notification

a)

Position/status

Non-executive Chairman

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Participation in Placing and Open Offer

d)

Price(s) and volume(s)

Price: 56p pence per share

Volume: 35,130 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

22 December 2020

f)

Place of the transactions

Off-market

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

Peter Presland

2.

Reason for the notification

a)

Position/status

Non-executive director

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Participation in Placing and Open Offer

d)

Price(s) and volume(s)

Price: 56p pence per share

Volume: 27,376 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

22 December 2020

f)

Place of the transactions

Off-market

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

Lisa Anson

2.

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Grant of options under the Redx All Employee Share Option Scheme

d)

Price(s) and volume(s)

Price: 56p pence per share

Volume: 11,683,586 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

22 December 2020

f)

Place of the transactions

Off-market

 

 

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

Richard Armer

2.

Reason for the notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Grant of options under the Redx All Employee Share Option Scheme

d)

Price(s) and volume(s)

Price: 56p pence per share

Volume: 5,984,378 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

22 December 2020

f)

Place of the transactions

Off-market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBFLLLBLLZFBV

Quick facts: Redx Pharma PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role. Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior...

on 19/7/18

13 min read